依奇珠单抗与阿达木单抗头对头比较:银屑病关节炎24周结果
该随机、开放标签、盲法评估者试验在未使用过生物制剂的活动性银屑病关节炎(PsA)患者中比较依奇珠单抗(IXE)与阿达木单抗(ADA)的疗效与安全性。24周时,IXE在同时达到ACR50和PASI100方面优于ADA(36% vs 28%,p=0.036),在PASI100也优于ADA(60% vs 47%,p=0.001),ACR50非劣于ADA(51% vs 47%,差值3.9%)。
要点
- IXE在同时改善关节与皮肤(ACR50+PASI100)方面优于ADA。
- IXE的PASI100应答优于ADA,ACR50应答非劣于ADA。
- 严重不良事件报告率ADA为8.5%,IXE为3.5%。
核心结论
- 在csDMARD应答不足的活动性PsA患者中,IXE在同时达到ACR50和PASI100方面优于ADA。
- 两种生物制剂的安全性和耐受性与已知安全性特征一致。
研究设计与样本
- 随机(1:1)、开放标签、头对头、盲法评估者临床试验。
- 纳入未使用过生物制剂且对csDMARD应答不足的活动性PsA伴皮肤病患者。
主要发现
- 主要终点达成:IXE组36%、ADA组28%同时达到ACR50和PASI100(p=0.036)。
- ACR50应答:IXE组51%、ADA组47%,治疗差值3.9%,IXE非劣于ADA。
- PASI100应答:IXE组60%、ADA组47%(p=0.001),IXE优于ADA。
- IXE在附加PsA、皮肤、指甲、达标治疗及生活质量结局方面应答优于ADA。
- 严重不良事件:ADA组8.5%,IXE组3.5%。
关键数值与推荐
- 主要终点:第24周同时达到ACR50和PASI100。
- 主要次要终点:第24周ACR50非劣效性和PASI100优效性。
临床怎么用
- 对于活动性PsA伴皮肤病变且csDMARD应答不足的患者,IXE可考虑作为改善关节和皮肤的综合治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To compare efficacy and safety of ixekizumab (IXE) to adalimumab (ADA) in biological disease-modifying antirheumatic drug-naïve patients with both active psoriatic arthritis (PsA) and skin disease and inadequate response to conventional synthetic disease-modifying antirheumatic drug (csDMARDs). METHODS: Patients with active PsA were randomised (1:1) to approved dosing of IXE or ADA in an open-label, head-to-head, blinded assessor clinical trial. The primary objective was to evaluate whether IXE was superior to ADA at week 24 for simultaneous achievement of a ≥50% improvement from baseline in the American College of Rheumatology criteria (ACR50) and a 100% improvement from baseline in the Psoriasis Area and Severity Index (PASI100). Major secondary objectives, also at week 24, were to evaluate whether IXE was: (1) non-inferior to ADA for achievement of ACR50 and (2) superior to ADA for PASI100 response. Additional PsA, skin, treat-to-target and quality-of-life outcome measures were assessed at week 24. RESULTS: The primary efficacy endpoint was met (IXE: 36%, ADA: 28%; p=0.036). IXE was non-inferior for ACR50 response (IXE: 51%, ADA: 47%; treatment difference: 3.9%) and superior for PASI100 response (IXE: 60%, ADA: 47%; p=0.001). IXE had greater response versus ADA in additional PsA, skin, nail, treat-to-target and quality-of-life outcomes. Serious adverse events were reported in 8.5% (ADA) and 3.5% (IXE) of patients. CONCLUSIONS: IXE was superior to ADA in achievement of simultaneous improvement of joint and skin disease (ACR50 and PASI100) in patients with PsA and inadequate response to csDMARDs. Safety and tolerability for both biologicals were aligned with established safety profiles.
引用
- Mease PJ, Smolen JS, Behrens F, et al. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann Rheum Dis. 2019. PMID: 31563894. doi:10.1136/annrheumdis-2019-215386
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。